Full-Time
Senior Manager
IT, Field Engagement Platforms
Posted on 9/4/2026
Mirum Pharmaceuticals
201-500 employees
ASBT inhibitors for rare liver diseases
Compensation Overview
$185k - $200k/yr
Foster City, CA, USA
Hybrid
Hybrid work arrangement indicated.
Bachelor's
 IT Operations (1) |
|---|
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
- Bachelor's degree in Computer Science, Information Systems, Engineering, Business, Life Sciences, or a related field.
- At least 5 years of experience supporting Commercial customer relationship management and field technology platforms.
- Experience as a customer relationship management product owner, platform owner, or technology lead responsible for roadmaps, backlogs, releases, integrations, operational support, and stakeholder management.
- Experience supporting field Commercial and/or Medical Affairs technology in a regulated environment.
- Deep functional and hands-on experience with Veeva CRM and capabilities including Approved Email, CLM, MyInsights, Veeva Network, Veeva OpenData, and PromoMats integrations.
- Strong understanding of life sciences field processes, including healthcare professional and healthcare organization engagement, customer segmentation, territories and alignments, call activity, content delivery, field communications, coaching, and field reporting.
- Strong understanding of customer relationship management data, customer master data, consent, integrations, analytics, and downstream Commercial data flows.
- Working knowledge of privacy, security, promotional and medical compliance, validation, and change-control expectations in life sciences.
- Strong product and platform management skills, including roadmap development, backlog prioritization, release planning, governance, and lifecycle management.
- Ability to influence without direct authority and coordinate business stakeholders, technical teams, vendors, and consultants.
- Strong communication and presentation skills, with the ability to translate technical considerations into clear business impact and decisions.
- Strong analytical, organizational, vendor-management, and problem-solving skills, with the ability to manage multiple priorities.
- Ability to balance strategic platform ownership with hands-on problem solving and operational accountability.
- Ability to build trusted partnerships with field users, business leaders, Compliance, and IT colleagues.
- Experience with documentation, testing, controls, release management, service management, and continuous improvement.
- Ability to make practical trade-offs across business value, user experience, compliance, cost, scalability, and maintainability.
- Serve as the IT product owner and primary technology lead for the global Veeva CRM ecosystem supporting field-based Commercial and Medical Affairs teams.
- Develop and maintain the platform strategy, multiyear roadmap, enhancement backlog, release plan, and lifecycle plan.
- Evaluate Veeva and third-party capabilities and recommend solutions based on business value, user experience, integration, scalability, security, compliance, cost, and maintainability.
- Provide recommendations on platform evolution and maintain clear boundaries and integration points with the Salesforce platform used for Patient Services and omnichannel engagement.
- Lead the design, configuration, testing, deployment, and support of Veeva CRM capabilities, including CLM, Approved Email, MyInsights, Coaching Reports, Key Insights, Key People, Veeva Network, Veeva OpenData, and PromoMats integrations.
- Ensure platform configuration aligns with field workflows, customer engagement requirements, data standards, consent and privacy requirements, compliance expectations, and user experience.
- Assess vendor roadmaps and release impacts, coordinate regression and user acceptance testing, and communicate changes to stakeholders.
- Identify opportunities to improve adoption, effectiveness, and workflow simplicity.
- Serve as the day-to-day IT relationship partner for field technology and develop an understanding of Sales and Medical Affairs operating models, workflows, user needs, and pain points.
- Translate business needs into process designs, functional requirements, user stories, acceptance criteria, and delivery plans.
- Facilitate prioritization with business and IT stakeholders based on strategic value, user impact, risk, effort, dependencies, capacity, and total cost.
- Partner with the Senior Director of IT on governance, investment recommendations, roadmap trade-offs, and executive communications.
- Lead change management, training coordination, release communications, and adoption activities.
- Partner with Data and Artificial Intelligence, integration, security, and infrastructure teams to ensure reliable and governed data flows across Veeva CRM, customer master data, territory and alignment platforms, analytics, content, consent, and other Commercial systems.
- Clarify system-of-record ownership, data definitions, interfaces, controls, monitoring, and support accountability for customer relationship management data and integrations.
- Ensure new capabilities integrate effectively with the broader Commercial and Medical Affairs technology ecosystem.
- Support data quality, reporting, analytics, automation, and responsible artificial intelligence opportunities that improve field effectiveness and decision-making.
- Establish and maintain platform governance, configuration standards, documentation, access controls, change controls, release procedures, and support processes.
- Ensure solutions meet promotional, medical, privacy, security, records-management, and regulatory requirements.
- Own service performance, production support, incident escalation, root-cause analysis, problem management, and continuity planning for the platform.
- Monitor platform usage, adoption, support trends, data quality, and user feedback; define and track service and product health measures.
- Manage platform risks, technical debt, upgrades, decommissioning, and remediation activities across the lifecycle.
- Lead cross-functional projects and enhancements from discovery through design, delivery, validation, deployment, stabilization, and value realization.
- Manage software vendors, implementation partners, consultants, and managed-service providers, ensuring accountability for scope, quality, timelines, service levels, knowledge transfer, and documentation.
- Develop project estimates and business cases; monitor platform and project spend with the Senior Director and IT leadership.
- Coordinate delivery dependencies, risks, decisions, and status reporting across business stakeholders and IT teams.
- Experience supporting Commercial CRM and field technology platforms in the pharmaceutical, biotechnology, or life sciences industry.
- Experience with Salesforce or adjacent omnichannel and Patient Services platforms, particularly where integration and platform-boundary decisions are required.
Mirum Pharmaceuticals develops and commercializes therapies for rare liver diseases. Its lead drug LIVMARLI (maralixibat) is an oral ASBT inhibitor that lowers bile acid buildup to relieve itching in cholestatic conditions such as Alagille syndrome, and the company is pursuing LIVMARLI for additional rare liver diseases, with volixibat as another ASBT inhibitor in its pipeline. The company differentiates itself by focusing on rare pediatric and adult cholestatic diseases and building dedicated commercialization infrastructure in the U.S. and other major markets, including partnerships with physicians, payers, and patient groups to improve patient access. Mirum’s goal is to bring effective therapies to patients with rare bile-duct and liver disorders, expand LIVMARLI indications, and establish a sustainable market presence in key markets.
Company Size
201-500
Company Stage
IPO
Headquarters
Foster City, California
Founded
2018
Get referred to Mirum Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 net product sales reached $176.2 million, and guidance rose to $700 million.
- Rob Myers starts September 21, 2026, strengthening hepatology leadership before key readouts.
- Volixibat, brelovitug, and zilurgisertib create multiple catalysts through first-half 2027.
What critics are saying
- FDA recommended another volixibat Phase 3 on August 5, 2026, delaying PSC filing.
- If LIVMARLI growth slows, Mirum loses the cash engine funding its pipeline.
- Zilurgisertib’s September 26, 2026 PDUFA denial would crush sentiment and financing flexibility.
What makes Mirum Pharmaceuticals unique
- LIVMARLI dominates rare pediatric cholestatic disease with expanding PFIC and biliary atresia labels.
- Mirum combines commercialization strength with late-stage hepatology pipeline breadth across PSC, HDV, and FOP.
- Exclusive zilurgisertib rights from Incyte add a near-term rare-disease launch platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Mirum Pharmaceuticals has appointed Dr Rob Myers as chief medical officer, effective 21 September 2026. Dr Myers will lead the company's global medical and clinical development functions. Dr Myers brings over 20 years of experience in drug development, with particular expertise in hepatology. He joins from OrsoBio, where he served as chief medical officer and head of development. Previously, he held senior leadership positions at Gilead Sciences, overseeing clinical development programmes across liver fibrosis, cholestatic liver diseases, and gastrointestinal inflammation. Dr Myers has published more than 200 peer-reviewed papers and has contributed to advancing understanding of primary sclerosing cholangitis. He holds an MD from Western University and a master's degree in epidemiology from the University of Calgary.
US FDA approves Regeneron's rare bone disorder drug. Regeneron's Pasatru has received US FDA approval for adults with FOP after clinical trials showed a significant reduction in abnormal bone formation. By Reuters August 20, 2026, 8:59:40 AM IST (Published) The US FDA on Wednesday (August 19) approved Regeneron's drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues. New York-based Regeneron's shares rose 4%. The drug, garetosmab, branded as Pasatru, was approved to treat adults with fibrodysplasia ossificans progressiva (FOP) - a condition in which muscle, tendon and ligament tissue gradually turns into bone, leading to a "second skeleton" that causes progressive loss of mobility and reduced life expectancy. In a 56-week trial involving 63 participants, Pasatru reduced the development of new bone abnormalities by 94% in patients treated with a 3 mg per kg dose and by 90% in those given a 10 mg per kg dose, compared with a placebo. The drug works by blocking Activin A, a protein involved in triggering abnormal bone growth in patients with FOP. Susan Rhee, a member of Regeneron's clinical team, told Reuters last week that the company plans to start a trial for children later this year. The drug will compete with French drugmaker Ipsen's oral treatment Sohonos, which in 2023 became the only other treatment approved by the US Food and Drug Administration. Incyte and partner Mirum Pharma, as well as privately held Ashibio, are also developing treatments for the condition. In 2020, Regeneron paused dosing in a mid-stage trial of the drug after five patient deaths, ultimately discontinuing the study and working with global regulators to design the late-stage trial, according to the company. The condition affects roughly 1 in 2 million people worldwide, with around 800 to 900 active diagnosed cases globally, according to data from the National Institutes of Health.
Mirum Pharmaceuticals shares plunged 15% on Thursday after the FDA recommended an additional Phase 3 study for its liver disease candidate Volixibat, potentially delaying the new drug application until the first half of 2027. Citizens lowered its price target to $137 from $146 whilst maintaining an Outperform rating. The regulatory setback overshadowed strong second-quarter results. Mirum reported revenue of $176.2 million, beating analysts' estimates of $167.3 million. The company raised its full-year net product sales guidance to $680 million to $700 million, from $660 million to $680 million. Mirum ended the quarter with $561.3 million in cash and equivalents. Volixibat has already received FDA Breakthrough Therapy and Orphan Drug designations.
Mirum Pharmaceuticals raised its full-year 2026 net product sales guidance to $680 million to $700 million, citing growth in Alagille syndrome and expanding adult PFIC diagnosis. The company secured $690 million through a convertible note offering, improving its capital structure whilst settling 75% of 2029 notes. The firm identified a significant opportunity in adult PFIC, estimating at least 2,000 addressable patients each in the US and Europe. Commercial operations achieved a high-50s percent cash contribution margin, representing a 5 percentage point year-over-year improvement. Mirum delayed its volixibat PSC NDA submission due to alignment issues with FDA reviewers but received Breakthrough Therapy Designation. The company targets a first-half 2027 NDA submission for PSC and anticipates Phase III PBC results in Q1 2027.
Mirum Pharmaceuticals reported revenue of $176.24 million for the quarter ended June 2026, up 37.9% year-over-year. The figure exceeded the consensus estimate of $164.76 million by 6.97%. The company posted a loss of $0.80 per share, compared to $0.12 a year ago, slightly missing the estimated loss of $0.77 per share. Product sales showed strong performance across categories. Livmarli generated $128.72 million, surpassing the $119.6 million analyst estimate. Bile acid medicines brought in $47.52 million, also beating expectations of $45.64 million. Despite beating revenue estimates, Mirum's shares fell 18.7% over the past month, underperforming the S&P 500's 3.5% gain.